Research has shown that EP receptors are involved in the progression of various cancers, including colorectal, breast, lung, and prostate cancers. Elevated levels of PGE2 and overexpression of EP receptors have been observed in these cancers, correlating with poor prognosis and increased resistance to therapy.
